Replies to post #246794 on Avid Bioservices Inc (CDMO)

[biopharm]

Jan25-26 2016: “GTCbio's Novel Immunotherapeutics Summit”, San Diego
..
..
1-26-15: SESSION: ”Combinatorial Immunotherapies” - Moderator: Bruce Freimark, Peregrine Pharm.
4 Speakers:

*9:35am “DNA Vaccines with T-Cell Checkpoint Blockade”, Douglas McNeel, UNIV./WISCONSIN

*10:00am “Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Targeted Therapy & Immune Checkpoint Inhibitors by Reducing Immunosuppressive Cells in the Tumor Microenvironment”, Bruce Freimark....

*10:25am “Cancer Vaccines in the Era of Checkpoint Blockade”, Willem Overwijk, MD.ANDERSON

*11:20am “Myeloid-Derived IL-10 & PD-1 Create a Vicious Immune...”, Keith Knutson, MAYO CLINIC
..
..

Thanks CJ and all I can say is without even looking into any of the other 3 speakers, besides Peregrine's Bruce Freimark, is that maybe we can assume that they are certainly part of the "dozens of collaborations.." alongside Peregrine.

-------------------------

just starting / taking one name from above => Keith Knutson and a little snapshot from this post below which was dated back in June 2015 when Ken Dart only owned 8 Million shares of PPHM verse today where Ken Dart owns over 30 Million shares of PPHM (13%+)

It also further validates the technology and the approach developed at Mayo Clinic by Professor Keith Knutson."

more to come

As mentioned before,TPIV wants publicity and to get off the bulletin board and onto the Nasdaq,it's obvious.

Kenneth Dart/Eastern Capital was holding only NASDAQ stocks before he grabbed a solid positing here. and proved he is buying more and more like he did just 2 weeks ago.

He owns 23million shares of VCEL, Vericel Corp. as well.
Owns 2million VSTM since Jan, 2015.
Owns 22million shares IBIO.
Owns 8million shares PPHM.
..
..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115037266

So now it may just be heading in the direction that Peregrine collaborates with Ken Dart companie(s) and more hints below...

------------

TapImmune Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board

June 12, 2014

TapImmune Inc. (TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company’s scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, a nonprofit biomedical research institute in Port St. Lucie, FL (VGTI Florida). TapImmune has licensed cancer vaccine technologies originating from Dr. Knutson’s former laboratory at the Mayo Clinic..
..

http://www.tapimmune.com/news/tapimmune-appoints-leading-immunotherapy-researcher-to-chair-scientific-advisory-board/

------------------------------------

I wonder what John Bonfiglio is strategically advising TapImmune to do .....

http://www.tapimmune.com/about-tapimmune/company-management/

-------------------------------------